South & Central America T Cell Therapy Market Forecast to 2030

South & Central America T Cell Therapy Market Forecast to 2030

South & Central America T Cell Therapy Market Forecast to 2030 – Regional Analysis – by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

Send Enquiry
Item ID: BMIRE00029318 Category: Tag:

$2,485 – $3,885

Description

The South & Central America T cell therapy market was valued at US$ 84.11 million in 2022 and is expected to reach US$ 265.59 million by 2030; it is estimated to grow at a CAGR of 15.5% from 2022 to 2030.

Increasing Number of T-Cell Therapy Approvals Fuels the South & Central America T Cell Therapy Market

Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approval:

• In 2023: Kite, a Gilead Company announced launching operations in Saudi Arabia, Singapore, and Brazil as part of its commercial expansion. Kite has filed regulatory applications for its CAR T-cell therapy products in each of the three nations.

• For instance, in June 2022, Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).

• In February 2022, the US Food and Drug Administration (FDA) approved Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first line chemoimmunotherapy or that relapses within 12 months of first line chemoimmunotherapy. Yescarta is the first CAR T-cell therapy to receive a National Comprehensive Cancer Network (NCCN) Category 1 recommendation.

• In February 2022, the FDA approved ciltacabtagene autoleucel (brand name CARVYKTI) for treating adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

• In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma patients who are HLA-A*02:01 positive.

• In March 2021, Abecma (idecabtagene vicleucel) was approved by the FDA for treating relapsed or refractory multiple myeloma. The treatment is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy indicated for treating adult patients with refractory multiple myeloma.

Therefore, the increasing number of approvals for T-cell therapies is fueling the market growth.

South & Central America T Cell Therapy Market Overview

The South & Central America T-cell therapy market is limited to Brazil as the products are only approved and commercially available in the country. According to the Brazilian Journal of Cancerology, it is estimated that ~704,000 new cases of cancer are expected during 2023-2025. More than 12,000 non-Hodgkin lymphoma (NHL) cases in Brazil are estimated to be diagnosed yearly. The Brazilian Health Regulatory Agency (ANVISA) has approved two CAR T-cell therapies in Brazil: tisagenlecleucel (by Novartis) for pediatric patients and young adults with RR B-cell acute lymphoblastic leukemia (ALL) and adults with relapsed/refractory (RR) diffuse large B-cell lymphoma, and ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM). Moreover, in August 2022, Kite, a Gilead Company, expanded its business by launching operations in Brazil, Singapore, and Saudi Arabia. Kite has submitted regulatory applications for its CAR T-cell therapy products. The rising cases of cancer and lymphoma, and the increasing number of applications and clinical trials for T-cell therapies are expected to boost the demand in the coming years.

South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

South & Central America T Cell Therapy Market Segmentation

The South & Central America T cell therapy market is segmented into modality , therapy type, indication, and country.

Based on modality, the South & Central America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the South & Central America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the South & Central America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the South & Central America T cell therapy market is limited to Brazil. Brazil dominated the South & Central America T cell therapy market share in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, and Novartis AG are some of the leading companies operating in the South & Central America T cell therapy market.

Summary Info

Industry:

Pricing options:

, ,

Publishing status:

Geographical coverage:

,

Year of Publication:

At 15.5% CAGR, the South & Central America T Cell Therapy Market is Speculated to be Worth US$ 265.59 million by 2030, says the research team

According to the research team’ research, the South & Central America T cell therapy market was valued at US$ 84.11 million in 2022 and is expected to reach US$ 265.59 million by 2030, registering a CAGR of 15.5% from 2022 to 2030. Growing burden of cancer worldwide and growing investment in T Cell therapy are among the critical factors attributed to the South & Central America T cell therapy market expansion.

According to World Health Organization (WHO), cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. According to the International Agency of Research on Cancer, in 2040, 30.2 million new cases will be added to the global cancer burden. Chimeric antigen receptor (CAR) T-cell therapies can potentially treat new type of cancer treatment that uses the immune system to fight cancer. CAR T involves genetically engineering T cells to express a chimeric antigen receptor targeting a specific tumor antigen. T-cell-based techniques are frequently used in cancer immunotherapy due to their higher success rate. In 2021, Labiotech.eu (a leading online media for the biotech industry in Europe) stated that more than 500 CAR T-cells clinical trials for cancer treatment are being carried out globally. Thus, the growing burden of cancer is driving the T-cell therapy market.

Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the T-cell therapy market.

On the contrary, side-effects of CAR T-cell therapy hampers on the growth of South & Central America T cell therapy market.

Based on modality, the South & Central America T cell therapy market is bifurcated into research and commercialized. The commercialized segment held 90.0% market share in 2022, amassing US$ 75.66 million. It is projected to garner US$ 244.21 million by 2030 to expand at 15.8% CAGR during 2022-2030.

Based on therapy type, the South & Central America T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held 100.0% share of South & Central America T cell therapy market in 2022, amassing US$ 84.11 million. It is projected to garner US$ 265.59 million by 2030 to expand at 15.5% CAGR during 2022-2030.

Based on indication, the South & Central America T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held 100.0% share of South & Central America T cell therapy market in 2022, amassing US$ 84.11 million. It is projected to garner US$ 265.59 million by 2030 to expand at 15.5% CAGR during 2022-2030.

Based on country, the South & Central America T cell therapy market has been categorized into Brazil. Our regional analysis states that Brazil captured 100.0% share of South & Central America T cell therapy market in 2022. It was assessed at US$ 84.11 million in 2022 and is likely to hit US$ 265.59 million by 2030, exhibiting a CAGR of 15.2% during 2022-2030.

Key players operating in the South & Central America T cell therapy market are Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, and Novartis AG, among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America T cell therapy market
o Highlights key in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in South & Central America T cell therapy market , thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 South & Central America T Cell Therapy Market, by Country (US$ Million)
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America T Cell Therapy Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Growing Burden of Cancer Worldwide
4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:
5. T Cell Therapy Market – South & Central America Market Analysis
5.1 South & Central America T Cell Therapy Market Revenue (US$ Mn), 2022 – 2030
6. South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 – by Modality.
6.1 Overview
6.2 South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
6.3.1 Overview
6.3.2 Research: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
6.4.1 Overview
6.4.2 Commercialized: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7. South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
7.1 Overview
7.2 South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
7.3.1 Overview
7.3.2 CAR T-cell Therapy: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
7.4.1 Overview
7.4.2 T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8. South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 – by Indication
8.1 Overview
8.2 South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
8.3.1 Overview
8.3.2 Hematologic Malignancies: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.3.3 South & Central America T Cell Therapy Market , by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
8.4.1 Overview
8.4.2 Solid Tumor: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. South & Central America T Cell Therapy Market – Country Analysis
9.1 Overview
9.1.1 South & Central America T Cell Therapy Market by Country
9.1.1.1 Brazil
9.1.1.1.1 Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.1.2 Brazil: South & Central America T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.1.3 Brazil: South & Central America T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.1.4 Brazil: South & Central America T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.1.4.1 Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10. T Cell Therapy Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Janssen Global Services LLC
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Gilead Sciences Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Bristol-Myers Squibb Co
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Novartis AG
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

LIST OF TABLES

Table 1. South & Central America T Cell Therapy Market Segmentation 8
Table 2. South & Central America T Cell Therapy Market , by Hematological Malignancies – Revenue and Forecast to 2030 (US$ Million)
Table 3. Brazil: South & Central America T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 4. Brazil: South & Central America T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 5. Brazil: South & Central America T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 6. Brazil: South & Central America T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 7. Recent Organic Growth Strategies in South & Central America T Cell Therapy Market
Table 8. Recent Inorganic Growth Strategies in the South & Central America T Cell Therapy Market
Table 9. Glossary of Terms, South & Central America T Cell Therapy Market

LIST OF FIGURES

Figure 1. South & Central America T Cell Therapy Market Segmentation, By Country 9
Figure 2. South & Central America T Cell Therapy Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. South & Central America T Cell Therapy Market Revenue (US$ Mn), 2022 – 2030
Figure 5. South & Central America T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. South & Central America T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. South & Central America T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: South & Central America T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. South & Central America T Cell Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 15. South & Central America T Cell Therapy Market , By Key Countries, 2022 and 2030 (%)
Figure 16. Brazil: South & Central America T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Growth Strategies in T Cell Therapy Market

The List of Companies – South & Central America T Cell Therapy Market

1. Bristol-Myers Squibb Co
2. Gilead Sciences Inc
3. Janssen Global Services LLC
4. Novartis AG

Reviews

There are no reviews yet.

Be the first to review “South & Central America T Cell Therapy Market Forecast to 2030”